Last reviewed · How we verify
Comparator: amlodipine besylate
Amlodipine besylate is a calcium channel blocker that relaxes blood vessels and reduces blood pressure by inhibiting calcium influx into vascular smooth muscle cells.
Amlodipine besylate is a calcium channel blocker that relaxes blood vessels and reduces blood pressure by inhibiting calcium influx into vascular smooth muscle cells. Used for Hypertension, Angina pectoris (chronic stable angina and vasospastic angina).
At a glance
| Generic name | Comparator: amlodipine besylate |
|---|---|
| Also known as | NORVASC® |
| Sponsor | Organon and Co |
| Drug class | Calcium channel blocker (dihydropyridine) |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Amlodipine selectively blocks L-type calcium channels in the membranes of vascular smooth muscle and cardiac muscle cells. By preventing calcium entry, it reduces intracellular calcium concentration, leading to vasodilation and decreased peripheral vascular resistance. This results in reduced blood pressure and improved coronary blood flow, making it effective for both hypertension and angina.
Approved indications
- Hypertension
- Angina pectoris (chronic stable angina and vasospastic angina)
Common side effects
- Peripheral edema
- Headache
- Flushing
- Fatigue
- Dizziness
- Palpitations
Key clinical trials
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- INTERVENCION Trial (PHASE4)
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia
- Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers (PHASE1)
- Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED) (PHASE4)
- An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: amlodipine besylate CI brief — competitive landscape report
- Comparator: amlodipine besylate updates RSS · CI watch RSS
- Organon and Co portfolio CI